Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma

References

• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Available from: https://ginasthma.org/gina-reports/. Accessed June 22, 2021.
   Google Scholar
• Czira A, Turner M, Martin A, et al. A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma. Respir Med. 2022;191:106670. doi:10.1016/j.rmed.2021.106670
   PubMed Web of Science ®Google Scholar
• McKeage K, Keam SJ. Salmeterol/fluticasone propionate. Drugs. 2009;69(13):1799–1828. doi:10.2165/11202210-000000000-00000
   PubMed Web of Science ®Google Scholar
• Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J. 2001;18(2):262–268. doi:10.1183/09031936.01.00065801
   PubMed Web of Science ®Google Scholar
• Hübner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin. 2005;25(3):469–488.
   PubMed Web of Science ®Google Scholar
• Cowie RL, Giembycz MA, Leigh R. Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children. Expert Opin Pharmacother. 2009;10(12):2009–2014. doi:10.1517/14656560903078428
   PubMed Web of Science ®Google Scholar
• Spada F, Barnes TM, Greive KA. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. Austral J Dermatol. 2018;59(3):e168–e174. doi:10.1111/ajd.12762
   PubMed Web of Science ®Google Scholar
• Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, Van As A. Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J. 2007;29(5):871–878. doi:10.1183/09031936.00060006
   PubMed Web of Science ®Google Scholar
• Beasley RW, Donohue JF, Mehta R, et al. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial. BMJ open. 2015;5(2):e006131. doi:10.1136/bmjopen-2014-006131
   PubMed Web of Science ®Google Scholar
• Murphy L, Rennard S, Donohue J, et al. Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD. Drugs. 2014;74(14):1635–1657. doi:10.1007/s40265-014-0284-7
   PubMed Web of Science ®Google Scholar
• Venkitakrishnan R, Augustine J. Inhaled steroid-Long acting beta two agonist (ICS-LABA) combinations in asthma: are all formulations the same? The Indian Journal of Tuberculosis. 2022;69:125–127. doi:10.1016/j.ijtb.2021.04.003
   PubMedGoogle Scholar
• Averell CM, Stanford RH, Laliberté F, Wu JW, Germain G, Duh MS. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. J Asthma. 2021;58(1):102–111. doi:10.1080/02770903.2019.1663429
   PubMed Web of Science ®Google Scholar
• Dal negro RW, Bonadiman L, Turco P, Varol Y, Kalenci D. Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg Bid: a 12-month comparison of outcomes in mild-to-moderate asthma. Multidiscip Respir Med. 2018;13(1):1–11. doi:10.1186/s40248-017-0116-1
   PubMedGoogle Scholar
• Inoue H, Milligan KL, McConnon A, et al. Uncontrolled asthma: a retrospective cohort study in Japanese patients newly prescribed with medium-/high-dose ICS/LABA. NPJ Prim Care Respir Med. 2021;31(1):1–10. doi:10.1038/s41533-021-00222-2
   PubMed Web of Science ®Google Scholar
• Nagase H, Adachi M, Matsunaga K, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2020;69(1):53–60. doi:10.1016/j.alit.2019.06.003
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Crimi N, et al. Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma. Expert Rev Respir Med. 2022;16(2):183–195. doi:10.1080/17476348.2021.2011222
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled Phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012. doi:10.1016/S2213-2600(20)30190-9
   PubMed Web of Science ®Google Scholar
• Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69–84. doi:10.1016/S2213-2600(20)30389-1
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207. doi:10.1056/NEJMoa1208606
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749. doi:10.1016/S0140-6736(19)32215-9
   PubMed Web of Science ®Google Scholar
• Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, Phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;106021. doi:10.1016/j.rmed.2020.106021
   PubMed Web of Science ®Google Scholar
• Buhl R, Kerstjens H, Nikolaev I, et al. Corresponding doses of mometasone furoate (MF) in once-daily inhaled fixed-dose combination (FDC) of indacaterol/mometasone furoate (IND/MF) and indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF): results from randomized clinical studies. J Allergy Clin Immunol. 2021;147(2):AB59. doi:10.1016/j.jaci.2020.12.235
   Web of Science ®Google Scholar
• van Zyl-Smit RN, Krüll M, Gessner C, et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. Lancet Respir Med. 2020;8:987–999. doi:10.1016/S2213-2600(20)30178-8
   PubMed Web of Science ®Google Scholar
• Kornmann O, Mucsi J, Kolosa N, et al. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: phase III randomised QUARTZ study findings. Respir Med. 2020;161:105809. doi:10.1016/j.rmed.2019.105809
   PubMed Web of Science ®Google Scholar
• Vaidya S, Jauernig J, Ethell B, et al. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. Pulm Pharmacol Ther. 2020;64:101964. doi:10.1016/j.pupt.2020.101964
   PubMed Web of Science ®Google Scholar
• Inoue S, Vaidya S, Tillmann H-C, et al. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects. BMC Pulm Med. 2021;21(1):1–12. doi:10.1186/s12890-020-01382-6
   PubMed Web of Science ®Google Scholar
• Chapman K, van Zyl-Smit R, Maspero J, et al. One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies. BMJ Open Respir Res. 2021;8(1):e000819. doi:10.1136/bmjresp-2020-000819
   PubMed Web of Science ®Google Scholar
• Chapman KR, van Zyl-Smit RN, Kerstjens HAM, et al. Evaluating contributions of mometasone (MF), indacaterol (IND) and glycopyrronium (GLY) to reduction of exacerbations in patients with inadequately controlled asthma: results from the IRIDIUM study. 2021.
   Google Scholar
• Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003;112(1):29–36. doi:10.1067/mai.2003.1558
   PubMed Web of Science ®Google Scholar
• Watz H, Hohlfeld JM, Singh D, et al. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study. Respir Res. 2020;21:1–5. doi:10.1186/s12931-020-01349-5
   PubMed Web of Science ®Google Scholar
• Zhang S, King D, Rosen VM, Ismaila AS. Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:417–438. doi:10.2147/COPD.S234823
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Fixed-dose combination inhalers. Handb Exp Pharmacol. 2017;237:117–129. doi:10.1007/164_2016_66
   PubMedGoogle Scholar